Torii Pharmaceutical Co (4551.T) Stock Price

Torii Pharmaceutical Co Price

JPX·CLOSED
23,528,002,435,891,200.00
​
Market closed

Over the last 19 years Torii Pharmaceutical Co grew revenue by 2.1% annually, reaching 60.43 B JPY. Earnings per share have grown at 1.0% per year over the last 19 years. For Torii Pharmaceutical Co, the net margin of 8.3% is broadly stable versus 8.4% a few years ago. At today's price the dividend yield works out to roughly 0.00%. The payout ratio is around 67% of earnings. The dividend has grown at 6.1% per year over the past 19 years.

Torii Pharmaceutical Co stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Torii Pharmaceutical Co business model & stock analysis

Torii Pharmaceutical Co Ltd is a Japanese pharmaceutical company founded in 1921. The company is headquartered in Tokyo and employs over 1,200 employees. Torii specializes in the development and manufacturing of medicines for the treatment of diseases such as diabetes, cancer, kidney and liver diseases, as well as allergic diseases and mental disorders. The business model of Torii is based on developing and manufacturing innovative medicines that have a high benefit for patients. To achieve this, the company invests a large portion of its revenue in research and development of new drugs. The goal is to improve both the quality of life of patients and support society by creating new healing opportunities. Torii is divided into two business segments: Pharma and Nutraceuticals. In the Pharma segment, the company produces prescription drugs that are primarily sold in Japanese hospitals and clinics. On the other hand, the Nutraceutical division offers products that are sold without a prescription and focus on dietary supplements and health-promoting products. Torii has a wide range of products, ranging from various medications to dietary supplements and functional foods. One of Torii's most well-known products is an antidiabetic called "Trelagliptin". The medication is used to treat type 2 diabetes and is the best-selling diabetes medication in Japan. Another important product from Torii is "UFT™", a chemotherapy treatment for cancer. UFT™ is particularly effective in treating stomach, colon, and lung cancer. Another significant medication is "Micardis™", a blood pressure-lowering medication. The medication lowers blood pressure without unwanted side effects and is also available in Europe and the United States. In the Nutraceutical division, Torii offers various products such as vitamins, minerals, dietary supplements, functional foods, and beverages. One highlight is "Real Gold Three", a dietary supplement that contains eight valuable herbs and focuses on improving the immune system. The product is sold in both Japan and China. In recent years, the company has established strategic partnerships with various other companies to promote innovation and accelerate growth. In 2019, the company signed a collaboration agreement with the Vietnamese division of the British pharmaceutical giant GlaxoSmithKline (GSK). The goal of the collaboration is to strengthen the distribution of GSK products in the Vietnamese market. Torii sees itself not only as a pharmaceutical company but also as part of society. The company actively supports social projects and corporate social responsibility (CSR). For example, Torii supports the "Operation Smile" program, which aims to help children with cleft lips and palates. Overall, Torii is an important player in the Japanese pharmaceutical market specializing in research, development, and marketing of innovative medicines. The company has a broad portfolio and has expanded its product range in recent years with various high-quality products. With its partnerships and social initiatives, Torii demonstrates that it is not only a commercial company but also makes an important contribution to society and the health of people.

Frequently asked questions about Torii Pharmaceutical Co

The business model of Torii Pharmaceutical Co Ltd revolves around the development, manufacturing, and sales of various pharmaceutical products. As a leading pharmaceutical company, Torii Pharmaceutical focuses on research and development to create innovative healthcare solutions. With a wide range of products spanning different therapeutic areas such as cardiovascular, respiratory, and central nervous system disorders, Torii Pharmaceutical aims to improve patient outcomes and enhance quality of life. Through strategic partnerships and collaborations, the company strives to expand its presence in both domestic and international markets, ensuring the delivery of high-quality and effective medications to patients worldwide.

Torii Pharmaceutical Co Ltd is primarily active in the pharmaceutical industry.

The main competitors of Torii Pharmaceutical Co Ltd in the market include companies such as Takeda Pharmaceutical Company Limited, Astellas Pharma Inc., Daiichi Sankyo Company Limited, Eisai Co., Ltd., and Shionogi & Co., Ltd.

Torii Pharmaceutical Co Ltd is a renowned pharmaceutical company with a rich history and background. Founded in 1921, Torii Pharmaceutical has been providing innovative healthcare solutions for nearly a century. The company specializes in developing and manufacturing high-quality prescription drugs, over-the-counter medications, and healthcare products. With a strong emphasis on research and development, Torii Pharmaceutical has earned a reputation for its commitment to improving global health. Through strategic partnerships and collaborations, the company has expanded its global presence, delivering its products to diverse markets. Torii Pharmaceutical continues to strive for excellence, ensuring the well-being of individuals worldwide through cutting-edge pharmaceutical advancements.

Since its establishment, Torii Pharmaceutical Co Ltd has reached several significant milestones. Notably, the company successfully launched its flagship product, Toubeauty®, an innovative skincare solution beloved by consumers worldwide. Torii Pharmaceutical Co Ltd also expanded its global presence by securing distribution agreements in key markets, further contributing to its growth and success. Additionally, the company has made strides in research and development, leading to the launch of groundbreaking pharmaceutical products that have positively impacted patients' lives. Overall, Torii Pharmaceutical Co Ltd continues to demonstrate its commitment to innovation, excellence, and improving the well-being of individuals through its remarkable achievements.

Torii Pharmaceutical Co Ltd is primarily present in Japan.

Torii Pharmaceutical Co Ltd represents values of excellence, integrity, and innovation. The company believes in delivering high-quality pharmaceutical products that improve the health and well-being of individuals. With a focus on research and development, Torii Pharmaceutical Co Ltd strives to provide innovative solutions and meet the changing needs of patients. The company's corporate philosophy emphasizes the importance of contributing to society through the development of safe and effective medications. By prioritizing patient-centric care, Torii Pharmaceutical Co Ltd aims to become a trusted partner in the global healthcare industry.

6 analysts currently rate the Torii Pharmaceutical Co stock: 4 recommend buying, 2 holding and 0 selling. For 2026, analysts expect Torii Pharmaceutical Co to generate revenue of 66.90 B JPY and earnings per share of 109.20 JPY.

Converted at the current exchange rate, the Torii Pharmaceutical Co share trades at 134.15 T EUR (23.53 TT JPY).

The Torii Pharmaceutical Co share (4551.T) is listed on 2 stock exchanges, including: Tokio (JPX) (4551.T).

Torii Pharmaceutical Co Ltd is a Japanese company specializing in the research, development, production, and marketing of pharmaceuticals. The company was founded in 1921 and is headquartered in Tokyo. The business model of Torii is based on developing and marketing innovative and effective drugs that contribute to improving the lives of patients. The company has a wide range of products in various therapy areas, such as cancer, cardiovascular diseases, metabolic disorders, immunology, and the nervous system. Torii operates in three main business areas: 1. Research and Development: Torii has an extensive research and development pipeline focused on novel drugs. The company invests heavily in the discovery and development of new pharmaceutical compounds and is constantly looking for promising technologies and therapies. 2. Manufacturing and Distribution: Torii has modern production facilities that meet the latest international standards to ensure that products are of high quality and safe. In addition, the company has an extensive distribution network in Japan and internationally to ensure that products can be delivered quickly and effectively to customers. 3. Brand Management: Torii markets and distributes its products under various brand names and is committed to raising awareness among the public and healthcare professionals. The company works closely with medical communities to maximize the effectiveness of its products and achieve broad market acceptance. Some of Torii's key products include: - Trelstar: A drug for the treatment of prostate cancer and endometriosis. - Edaravone: A neuroprotective drug for the treatment of amyotrophic lateral sclerosis (ALS). - Remitch: A drug for the treatment of sleep disorders. - Coniel: A drug for the treatment of hypertension. Torii also pursues a strategy of collaborating with other pharmaceutical companies to accelerate the development of new drugs and expand its global market presence. The company has already successfully formed partnerships with major international pharmaceutical companies such as Sanofi and Pfizer. Overall, Torii's business model aims to be a leading provider of pharmaceuticals that maintains a competitive position in the market through innovative technology, excellent product quality, and strong partnerships with other companies.

The expected revenue of Torii Pharmaceutical Co is 66.90 B JPY. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Torii Pharmaceutical Co is 3.07 B JPY. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Torii Pharmaceutical Co is currently 215.46 T. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Torii Pharmaceutical Co stock.

The price-to-sales ratio (P/S) of Torii Pharmaceutical Co is currently 9.89 T. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Torii Pharmaceutical Co stock.

The Eulerpool Quality Score for Torii Pharmaceutical Co is 6/10.

The ISIN of Torii Pharmaceutical Co is JP3635800000. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Torii Pharmaceutical Co is 887536. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Torii Pharmaceutical Co is 4551.T. The ticker symbol is used to trade Torii Pharmaceutical Co shares on the stock exchange.

Fair ValueTerminal
22.82 TT JPY
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Pharmaceuticals
Number of shares
Employees
Revenue per Employee
91.55 M JPY
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Website torii.co.jp
Country
Currency
JPY
Initial public offering
Oct 1, 2013
ISIN
JP3635800000
Cusip
J8959J102
Sedol
6896894
Market capitalization
52-Week Range
PEG
41.10 T
P/E ratio
P/Ee 2025
156.33 T
P/Ee 2026
215.46 T
P/Ee 2027
137.75 T
P/Ee 2028
163.73 T
P/Ee 2029
133.61 T
P/Se
9.80 T
EV/EBIT
97.29 T
P/B Ratio
5.44 T
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
4.13 %
Dividend
Dividend yield
0.00 %
Est. Dividend Yield
0.00 %
Payout Ratio
66.90 %
Dividend growth Ø5Y
30.26 %
Dividend payments per year
2
Dividend paid since
36 years
Dividend not reduced since
10 years
Dividend increased since
0 years
Dividend withholding tax
15.32 %
Last updated Nov 20, 2026, 9:14 PM

Torii Pharmaceutical Co Ticker

JPX · 4551.TOTC · TRXPF

Torii Pharmaceutical Co FIGI

4551:JP · BBG000BCWRW04551:JT · BBG000BCWSL04551:JJ · BBG000BCWYZ24551:JE · BBG000BCX0D94551:JI · BBG000BCX101TRXPF:US · BBG000BXRD24TRXPF:UV · BBG000BXRMG94551:JU · BBG002QK8P444551:JW · BBG00875F1B24551JPY:XS · BBG00L4B1S654551JPY:XH · BBG00L4B1S924551JPY:XF · BBG00L4B1SC8

All fundamentals and in-depth analysis of Torii Pharmaceutical Co

Our stock analysis for Torii Pharmaceutical Co stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Torii Pharmaceutical Co. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.